Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry

Christie M. Ballantyne, Robert C. Bourge, Leslie J. Domalik, Howie J. Eisen, Daniel P. Fishbein, Spencer H. Kubo, Kathleen D. Lake, Branislav Radovancevic, David O. Taylor, Hector O. Ventura, Clyde W. Yancy, James B. Young

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Hyperlipidemia occurs frequently after heart transplantation, and accelerated coronary artery disease remains the major cause of morbidity and mortality in patients who survive more than 1 year after heart transplantation. However, the risks and benefits of lipid-lowering therapy after heart transplantation remain poorly defined, and national guidelines for lipid-lowering drug therapy do not specifically address treatment of dyslipidemia in transplant recipients. Since the initial reports in the 1980s of rhabdomyolysis in heart transplant patients receiving high-dosage lovastatin, results of 11 post-transplantation series that used lovastatin, simvastatin, or pravastatin at lower dosages as drug monotherapy have been published. These studies have shown an overall 1% incidence of rhabdomyolysis, defined as creatine kinase > 10 times the upper limit of normal plus muscle symptoms. One randomized, controlled prospective trial has investigated the effects of lipid-lowering pharmacotherapy on patient outcome in cardiac transplant recipients. At 1 -year follow-up in this nonblinded, single-center trial, patients treated with pravastatin (20 or 40 mg/day) initiated within 2 weeks of transplantation had a significant reduction in mortality rate and a significantly lower incidence of transplant arteriopathy. A number of important issues remain unanswered regarding treatment guidelines in patients with hyperlipidemia after heart transplantation. In January 1995 we began the Heart Transplant Lipid Registry, with 12 participant centers, to gather data prospectively on the efficacy and safety of lipid-lowering drugs in the treatment of dyslipidemia after heart transplantation.

Original languageEnglish (US)
Pages (from-to)532-535
Number of pages4
JournalAmerican Journal of Cardiology
Volume78
Issue number5
DOIs
StatePublished - Jan 1 1996

Fingerprint

Heart Transplantation
Hyperlipidemias
Registries
Transplants
Lipids
Pravastatin
Lovastatin
Rhabdomyolysis
Dyslipidemias
Transplantation
Guidelines
Therapeutics
Drug Therapy
Simvastatin
Mortality
Incidence
Creatine Kinase
Pharmaceutical Preparations
Coronary Artery Disease
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ballantyne, Christie M. ; Bourge, Robert C. ; Domalik, Leslie J. ; Eisen, Howie J. ; Fishbein, Daniel P. ; Kubo, Spencer H. ; Lake, Kathleen D. ; Radovancevic, Branislav ; Taylor, David O. ; Ventura, Hector O. ; Yancy, Clyde W. ; Young, James B. / Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. In: American Journal of Cardiology. 1996 ; Vol. 78, No. 5. pp. 532-535.
@article{7444f152c1e343fbb652d60662943c44,
title = "Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry",
abstract = "Hyperlipidemia occurs frequently after heart transplantation, and accelerated coronary artery disease remains the major cause of morbidity and mortality in patients who survive more than 1 year after heart transplantation. However, the risks and benefits of lipid-lowering therapy after heart transplantation remain poorly defined, and national guidelines for lipid-lowering drug therapy do not specifically address treatment of dyslipidemia in transplant recipients. Since the initial reports in the 1980s of rhabdomyolysis in heart transplant patients receiving high-dosage lovastatin, results of 11 post-transplantation series that used lovastatin, simvastatin, or pravastatin at lower dosages as drug monotherapy have been published. These studies have shown an overall 1{\%} incidence of rhabdomyolysis, defined as creatine kinase > 10 times the upper limit of normal plus muscle symptoms. One randomized, controlled prospective trial has investigated the effects of lipid-lowering pharmacotherapy on patient outcome in cardiac transplant recipients. At 1 -year follow-up in this nonblinded, single-center trial, patients treated with pravastatin (20 or 40 mg/day) initiated within 2 weeks of transplantation had a significant reduction in mortality rate and a significantly lower incidence of transplant arteriopathy. A number of important issues remain unanswered regarding treatment guidelines in patients with hyperlipidemia after heart transplantation. In January 1995 we began the Heart Transplant Lipid Registry, with 12 participant centers, to gather data prospectively on the efficacy and safety of lipid-lowering drugs in the treatment of dyslipidemia after heart transplantation.",
author = "Ballantyne, {Christie M.} and Bourge, {Robert C.} and Domalik, {Leslie J.} and Eisen, {Howie J.} and Fishbein, {Daniel P.} and Kubo, {Spencer H.} and Lake, {Kathleen D.} and Branislav Radovancevic and Taylor, {David O.} and Ventura, {Hector O.} and Yancy, {Clyde W.} and Young, {James B.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0002-9149(96)00358-X",
language = "English (US)",
volume = "78",
pages = "532--535",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

Ballantyne, CM, Bourge, RC, Domalik, LJ, Eisen, HJ, Fishbein, DP, Kubo, SH, Lake, KD, Radovancevic, B, Taylor, DO, Ventura, HO, Yancy, CW & Young, JB 1996, 'Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry', American Journal of Cardiology, vol. 78, no. 5, pp. 532-535. https://doi.org/10.1016/S0002-9149(96)00358-X

Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. / Ballantyne, Christie M.; Bourge, Robert C.; Domalik, Leslie J.; Eisen, Howie J.; Fishbein, Daniel P.; Kubo, Spencer H.; Lake, Kathleen D.; Radovancevic, Branislav; Taylor, David O.; Ventura, Hector O.; Yancy, Clyde W.; Young, James B.

In: American Journal of Cardiology, Vol. 78, No. 5, 01.01.1996, p. 532-535.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry

AU - Ballantyne, Christie M.

AU - Bourge, Robert C.

AU - Domalik, Leslie J.

AU - Eisen, Howie J.

AU - Fishbein, Daniel P.

AU - Kubo, Spencer H.

AU - Lake, Kathleen D.

AU - Radovancevic, Branislav

AU - Taylor, David O.

AU - Ventura, Hector O.

AU - Yancy, Clyde W.

AU - Young, James B.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Hyperlipidemia occurs frequently after heart transplantation, and accelerated coronary artery disease remains the major cause of morbidity and mortality in patients who survive more than 1 year after heart transplantation. However, the risks and benefits of lipid-lowering therapy after heart transplantation remain poorly defined, and national guidelines for lipid-lowering drug therapy do not specifically address treatment of dyslipidemia in transplant recipients. Since the initial reports in the 1980s of rhabdomyolysis in heart transplant patients receiving high-dosage lovastatin, results of 11 post-transplantation series that used lovastatin, simvastatin, or pravastatin at lower dosages as drug monotherapy have been published. These studies have shown an overall 1% incidence of rhabdomyolysis, defined as creatine kinase > 10 times the upper limit of normal plus muscle symptoms. One randomized, controlled prospective trial has investigated the effects of lipid-lowering pharmacotherapy on patient outcome in cardiac transplant recipients. At 1 -year follow-up in this nonblinded, single-center trial, patients treated with pravastatin (20 or 40 mg/day) initiated within 2 weeks of transplantation had a significant reduction in mortality rate and a significantly lower incidence of transplant arteriopathy. A number of important issues remain unanswered regarding treatment guidelines in patients with hyperlipidemia after heart transplantation. In January 1995 we began the Heart Transplant Lipid Registry, with 12 participant centers, to gather data prospectively on the efficacy and safety of lipid-lowering drugs in the treatment of dyslipidemia after heart transplantation.

AB - Hyperlipidemia occurs frequently after heart transplantation, and accelerated coronary artery disease remains the major cause of morbidity and mortality in patients who survive more than 1 year after heart transplantation. However, the risks and benefits of lipid-lowering therapy after heart transplantation remain poorly defined, and national guidelines for lipid-lowering drug therapy do not specifically address treatment of dyslipidemia in transplant recipients. Since the initial reports in the 1980s of rhabdomyolysis in heart transplant patients receiving high-dosage lovastatin, results of 11 post-transplantation series that used lovastatin, simvastatin, or pravastatin at lower dosages as drug monotherapy have been published. These studies have shown an overall 1% incidence of rhabdomyolysis, defined as creatine kinase > 10 times the upper limit of normal plus muscle symptoms. One randomized, controlled prospective trial has investigated the effects of lipid-lowering pharmacotherapy on patient outcome in cardiac transplant recipients. At 1 -year follow-up in this nonblinded, single-center trial, patients treated with pravastatin (20 or 40 mg/day) initiated within 2 weeks of transplantation had a significant reduction in mortality rate and a significantly lower incidence of transplant arteriopathy. A number of important issues remain unanswered regarding treatment guidelines in patients with hyperlipidemia after heart transplantation. In January 1995 we began the Heart Transplant Lipid Registry, with 12 participant centers, to gather data prospectively on the efficacy and safety of lipid-lowering drugs in the treatment of dyslipidemia after heart transplantation.

UR - http://www.scopus.com/inward/record.url?scp=10644219635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644219635&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(96)00358-X

DO - 10.1016/S0002-9149(96)00358-X

M3 - Article

C2 - 8806337

AN - SCOPUS:10644219635

VL - 78

SP - 532

EP - 535

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -